FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
出版年份 2018 全文链接
标题
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
作者
关键词
-
出版物
Future Oncology
Volume 14, Issue 17, Pages 1669-1678
出版商
Future Medicine Ltd
发表日期
2018-02-09
DOI
10.2217/fon-2017-0646
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
- (2017) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives
- (2016) Nicoletta Colombo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data
- (2016) Masahiko Nakayama et al. GYNECOLOGIC ONCOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
- (2016) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
- (2015) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
- (2015) Ignace B. Vergote et al. CANCER AND METASTASIS REVIEWS
- Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
- (2015) Andres M. Poveda et al. JOURNAL OF CLINICAL ONCOLOGY
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Ovarian cancer standard of care: are there real alternatives?
- (2015) Chiara Della Pepa et al. Chinese Journal of Cancer
- High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction
- (2015) Victor S. Goldmacher et al. PLoS One
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
- (2014) J. Liu et al. CLINICAL CANCER RESEARCH
- The folate receptor as a rational therapeutic target for personalized cancer treatment
- (2014) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review
- (2014) Claudia Marchetti et al. OncoTargets and Therapy
- Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
- (2014) Daniela Luvero et al. Therapeutic Advances in Medical Oncology
- Expression of Folate Receptor-α (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type
- (2013) Daniel J. O’Shannessy et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
- (2011) Maurie Markman Cancer Management and Research
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2010) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Weekly paclitaxel in the treatment of recurrent ovarian cancer
- (2010) Richard D. Baird et al. Nature Reviews Clinical Oncology
- Current role and future aspects of topotecan in relapsed ovarian cancer
- (2009) Jalid Sehouli et al. CURRENT MEDICAL RESEARCH AND OPINION
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now